DEADLINE NEXT WEEK: Investors with Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit – OCGN

SAN DIEGO–(BUSINESS WIRE) –Robbins Geller Rudman & Dowd LLP Announces the class action lawsuit by Ocugen, Inc. charged Ocugen, Inc. (NASDAQ: OCGN) and certain of its executives of violating the Securities Exchange Act of 1934 and seeking buyers of Ocugen securities between February 2, 2021 and June to represent 10th 2021, inclusive (the “Class Period”). The class action lawsuit against Ocugen (Nicanor v. Ocugen, Inc., No. 21-cv-02725) began on June 17, 2021 and is pending in the Eastern District of Pennsylvania.

If you have suffered significant losses and wish to serve as the lead plaintiff in the Ocugen class action, please provide your information by clicking here. You can also contact Attorney JC Sanchez of Robbins Geller by phone at 800 / 449-4900 or by email at [email protected]. Lead plaintiffs’ class action lawsuit against Ocugen must be filed with the court by August 17, 2021.

CLAIM: Ocugen’s class action alleges that defendants made false and misleading statements during the class action period and failed to disclose: (i) the information Ocugen provided to the US Food and Drug Administration (“FDA”) , were insufficient to support an Emergency Use Authorization (“EUA”); (ii) Ocugen would not file an EEA with the FDA; and (iii) as a result, Ocugen’s financial statements and Defendants’ statements regarding Ocugen’s business, operations and prospects were false, misleading and / or unfounded.

On June 10, 2021, Ocugen issued a press release announcing that it would pursue a Biological Drugs (“BLA”) application with the FDA in place of the previously announced EUAs. Ocugen revealed that “[t]The FDA gave Ocugen feedback on the Master File the company had previously submitted, recommending Ocugen to pursue a BLA filing instead of an EUA application for its vaccine candidate and requesting additional information and data. Ocugen is in discussion with the FDA to understand the additional information required to support a BLA filing. The company believes that data from an additional clinical trial will be needed to support the filing. ”On the basis of this news, Ocugen shares fell more than 28%, causing harm to investors.

LEAD ACTION: The Private Securities Litigation Reform Act of 1995 allows any investor who has purchased Ocugen securities during the class action period to seek appointment as the lead plaintiff in the Ocugen class action. A lead plaintiff is usually the applicant with the greatest financial interest in the legal protection sought by the alleged class, which is also typical and appropriate for the alleged class. A lead plaintiff is acting on behalf of all the other group members in directing the Ocugen class action. The lead plaintiff can choose a law firm of their choice to bring the Ocugen class action lawsuit. An investor’s ability to participate in a possible future recovery of the Ocugen class action does not depend on whether they are the lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm serving investors in securities class actions. Robbins Geller’s attorneys have secured many of the largest shareholder recoveries in history, including the largest securities class action of all time – $ 7.2 billion – in In re Enron Corp. Sec. Lit. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for getting $ 1.6 billion back for investors last year, more than double the amount paid by any other securities plaintiff firm was drafted. Please visit https://www.rgrdlaw.com/firm.html for more information.

Lawyer advertising.

Past results do not guarantee future results.

Services can be performed by lawyers in any of our offices.

Comments are closed.